HUMA 241220 4.00C (HUMA241220C4000) Stock Options, News & Quotes

US OptionsDetailed Quotes

HUMA241220C4000

Watchlist

0.64
0.000.00%

15min DelayTrading Dec 20 16:00 ET

0.00High0.00Low

Intraday

5D
Daily

News

Individual Investors Who Own 46% Along With Institutions Invested in Humacyte, Inc. (NASDAQ:HUMA) Saw Increase in Their Holdings Value Last Week
Simply Wall StDec 25 06:44 ET
Microsoft To Rally Around 26%? Here Are 10 Top Analyst Forecasts For Monday
BenzingaDec 23 11:00 ET
Humacyte Is Maintained at Buy by Benchmark
Dow JonesDec 23 09:31 ET · Ratings
Benchmark Co. Maintains Humacyte(HUMA.US) With Buy Rating, Raises Target Price to $17
Moomoo NewsDec 23 07:31 ET · Ratings
Analysts Offer Insights on Healthcare Companies: Humacyte (HUMA) and Ligand Pharma (LGND)
TipRanksDec 23 06:50 ET · Ratings
Express News | Humacyte Inc : Benchmark Raises Target Price to $17 From $15
ReutersDec 23 06:24 ET

Comments

Bullish Investor

2 hours ago

Expect the unexpected.

$Humacyte (HUMA.US)$

Invest with Sarge

Dec 27 10:44

Humacyte (HUMA

Potentially breaking out from a downward sloping Raff Regression model. I am long $Humacyte (HUMA.US)$ .

Flowerhill

Dec 27 08:38

$Humacyte (HUMA.US)$ Finally going up for real?

102823122

Dec 23 07:49

$Humacyte (HUMA.US)$ will it cross $5.1 today

tough Hamster_1496

Dec 23 02:20

DoD

$Humacyte (HUMA.US)$
FDA delay in approving Humacyte stemmed from national security concerns - developed in collaboration with the DoD. An undeniable strategic advantage for the U.S. military.
The fact that we have a +10 billion $ runway is just nice to know.